


Preliminary Results Presentation

For the year ending 31st December 2007






Disclaimer

- This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been verified by Plethora Solutions Holdings plc (the “Company”) or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.
- This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements and capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

Delivering a Sustainable Urology Company



Plethora Product Portfolio

Symptoms	Product	Pre-Clinical	Phase I / Pilot	Phase II	Phase III	Market	Marketing Channel	
Erectile Dysfunction	ErecAid®	[Progress bar: Pre-Clinical to Phase III]						
	Rigiscan®	[Progress bar: Pre-Clinical to Phase III]						
	Invicorp®	[Progress bar: Pre-Clinical to Phase II]						
Premature Ejaculation	PSD401	[Progress bar: Pre-Clinical to Phase III]						
	PSD502	[Progress bar: Pre-Clinical to Phase II]						
	PSD502 (Pain)	[Progress bar: Pre-Clinical to Phase II]						
Urinary Incontinence	PSD503	[Progress bar: Pre-Clinical to Phase II]						
	PSD506	[Progress bar: Pre-Clinical to Phase I]						
Uro-Gyn	PSD597	[Progress bar: Pre-Clinical to Phase II]						
	PSD508	[Progress bar: Pre-Clinical to Phase I]						
	PSD509	[Progress bar: Pre-Clinical to Phase I]						

FY2007 Highlights

Product Revenues

- Revenues of £5.8m (2006 £5.2m)
- Gross profit of 86% (2006: 79%)

Licensing

- PSD502: Sciele licensing agreement for the USA
- Co-Promotion rights retained for the USA
- Non-US rights in negotiation
- Additional products now at licensing stage

Development


- PSD502: Completion of US IND study, initiation of Phase III programme
- PSD597: Completion of Phase II study
- PSD503: Completion of Phase II study
- PSD510: Clearance from FDA to proceed to pivotal study

Male Health Franchise

Product	Indication	Category	Status	Launch Schedule
ErecAid	ED	Device	Marketed	Launched
PSD502	PE	Therapeutic	Phase III	2009 - 2010
PSD510 'Invicorp'	ED	Therapeutic	Phase II/III	2009 - 2010

Timm Medical – ED Product Sales

- Devices for the treatment of ED
- FY07 sales of £5.8m (FY06 £5.2m)
- Gross margin improvement to 86% from 79%
- Sales force expanded by 20%
- Growth in ErecAid sales to post radical prostatectomy patients
- Initiated clinical programmes for failed medical management patients and brachytherapy patients



PSD502: Phase III Completion in 2008

- Safe and effective metered aerosol delivery with fast onset of action to treat PE
- Status:
 - Phase II completed successfully
 - US IND opened with pK study, completed in 06.07 confirming safety and tolerability
 - Positive meetings with US and European regulators confirmed Phase III protocol - comprises 540 patients from two studies
- Outlook:
 - Phase III scheduled to complete Q4 08
 - Ongoing ex-US licensing discussion




PSD510: Invicorp[®] for Erectile Dysfunction

Product	Non-oral drug for patients refractory or contra-indicated for oral ED medication
Rights	Exclusive North American rights, potential patient pool of 2.6m men
Status	New IP established. Positive outcome to FDA meeting. Two Phase III studies planned: Study 1: Post RP patients, 450 patients, Study 2: Wider label, 300 patients, novel auto-injector, 6 month study
Outlook	Objective is approval for first indication by YE'09.

	Caverject [®] Impulse	MUSE [®]	Invicorp [®]
Pain	37%	32% (penile) 12% (urethral)	0% in 2 studies (~6000 injections), 11% one study

Male Health Franchise



- Sciele and future OUS agreements contribute milestones and royalties
- Product sales driven through Timm Medical

Women's Health Franchise

Product	Indication	Description	Status
PSD597	Interstitial cystitis	Therapeutic	Phase II
PSD503	SUI	Therapeutic	Phase II
PSD506	OAB (LUTS)	Therapeutic	Phase II
PSD508	Dysmenorrhoea	Therapeutic	Phase II
PSD509	Uterine pain	Therapeutic	Pre Phase II

PSD597: Treatment for Interstitial Cystitis

Product	Therapy for the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS)
Market Potential	Treatment population of c.2m women, poorly met medical need
Clinical Objective	Immediate and sustained pain control
Status	Multi-centre US Phase II, n= 90, Complete, positive outcome reported 06.09.07.
Study	Relief of bladder pain and IC symptoms. Secondary study in an acute bladder indication
Pre-clinical	Potential micelle formulation of API

One of few double blind placebo controlled study using well recognised GRA outcome measure to report positive

Statistically and clinically significant improvement in IC/PBS symptoms
 Treatment effect sustained beyond first dosing
 Safe and well tolerated
 86% patients elected to progress into the open label study

Population	Severe symptoms	Market potential*	Moderate symptoms	Market potential
US	94,000	\$113m	68,000	\$82m
Europe	260,000	\$312m	148,000	\$178m
Total		\$425m		\$260m

PSD503 for SUI

Product	Therapy for the treatment of female Stress Urinary Incontinence
Market Potential	Treatment population of c.20m women, no universally approved pharmaceutical
Clinical Objective	Dryness and no associated elevation of blood pressure
Status	Phase II data reported 12.2007
Study	Placebo controlled crossover study in women with SUI. Endpoints included pad weights and CV Profile (safety).

- 45% improvement in primary endpoint pad weight vs placebo (12% increase in pad weight)
- 50% of individuals had improvement over placebo (good responder rate for a urological condition)
- Cardiovascular profiles similar for placebo and PSD503
- Low plasma phenylephrine levels




Women's Health Franchise: PSD506 & 508

Product	PSD506 - Oral anti-muscarinic for the treatment of overactive bladder (OAB) in woman and LUTS in men
Benefit	Benign safety profile, reduced urinary urgency and convenient dosing
Status	Multi-study Phase II programme – Positive data from dose ranging study in spinal injury patients
Product	PSD508 - Intra-vaginal delivery of NSAID for the treatment of dysmenorrhoea
Benefit	Rapid relief from menstrual pain, dosing on-demand, benign safety profile
Status	Phase II initiated late 2007, recruitment completed 04.08, data Q3 2008

FY2007: Group Income Statement

	Year to 31 December 2007 £'000s	Year to 31 December 2006 £'000s
Revenues	5,766	5,158
Cost of Goods	(789)	(1,071)
Gross Profit	4,977	4,087
Central & General	(3,217)	(1,568)
Sales & Marketing	(4,078)	(3,191)
Development	(8,196)	(5,402)
Amortisation of intangibles	(464)	(418)
Total Operating Costs	(15,955)	(10,579)
Operating Loss	(10,978)	(6,492)
Finance income/(cost)	(264)	253
Tax credit	764	344
Profit /(Loss) for the Year	(10,478)	(5,895)

Current Clinical Development Pipeline



FY2007: Summarised Group Balance Sheet & Cash Flow Statement

	At 31 December 2007 £000s	At 31 December 2006 £000s
Non current Assets	6,123	6,706
Cash	2,595	3,439
Other current assets	2,243	1,319
Current liabilities	(5,409)	(2,027)
Non current liabilities	(3,885)	(2,068)
Net assets	1,667	7,369
Net cash outflows from operations	(8,853)	(5,206)
Net cash from investing activities	83	(4,863)
Cash outflow before financing	(8,770)	(10,069)
Net cash from financing	7,926	7,295
Net decrease in cash and cash equivalents	(844)	(2,774)

Outlook

- Execution of development pipeline funded via Paul Capital Healthcare (PCH) facility (01.04.08)
- Short term value inflection potential with Phase III data within 12 months (PSD502/510)
- Multiple projects now moving into licensing discussions
- Double digit sales growth in the US – potential for future product acquisitions
- Continuing review of acquisition opportunities – potential support from PCH and ETV
- Strategy on track to deliver a sustainable urology business